Aduro Biotech | Discovering and Developing Immunotherapies.

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight diseases

STING Pathway

APRIL Pathway

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2018 Annual Report

Recent News

February 06, 2020 Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer

January 09, 2020 Aduro Biotech Announces Corporate Restructuring

November 08, 2019 Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?